Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, November 5th. Analysts expect the company to announce earnings of ($1.13) per share for the quarter.
Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share for the quarter, topping analysts' consensus estimates of ($0.91) by $0.11. The business had revenue of $3.50 million during the quarter. The firm's revenue for the quarter was up 3499999990.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.64) EPS. On average, analysts expect Syndax Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Syndax Pharmaceuticals Trading Down 0.7 %
Shares of NASDAQ SNDX traded down $0.14 during mid-day trading on Wednesday, reaching $18.94. The company had a trading volume of 269,049 shares, compared to its average volume of 1,049,945. Syndax Pharmaceuticals has a 52 week low of $12.95 and a 52 week high of $25.34. The business's 50-day moving average is $19.20 and its 200-day moving average is $20.38. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -5.87 and a beta of 0.91.
Analyst Ratings Changes
A number of brokerages have recently commented on SNDX. JPMorgan Chase & Co. reduced their target price on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 6th. Stifel Nicolaus raised their price objective on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a "buy" rating in a report on Monday, October 14th. UBS Group assumed coverage on Syndax Pharmaceuticals in a report on Thursday, October 24th. They issued a "buy" rating and a $37.00 target price for the company. Citigroup raised their price target on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a "buy" rating in a research note on Friday, August 16th. Finally, HC Wainwright upped their price objective on shares of Syndax Pharmaceuticals from $41.00 to $45.00 and gave the stock a "buy" rating in a research note on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $35.90.
View Our Latest Stock Report on Syndax Pharmaceuticals
Syndax Pharmaceuticals Company Profile
(
Get Free Report)
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
Read More
Before you consider Syndax Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.
While Syndax Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.